Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
U.S. FDA expands authorization of Pfizer bivalent COVID-19 shots in kids
© Reuters. FILE PHOTO: Scarlett Orangers receives a dose of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at a booster clinic for 12 to 17-year-olds in Lansdale, Pennsylvania, U.S., January 9, 2022. REUTERS/Hannah Beier
(Reuters) - Pfizer Inc (NYSE:PFE) said on Tuesday that the U.S. Food and Drug Administration had expanded the emergency use authorization (EUA) of the company and its partner BioNTech SE (NASDAQ:BNTX)'s bivalent COVID-19 vaccine as a single booster dose in certain children.
The amended authorization is for children six months through four years of age who have completed their initial three-dose vaccination with Pfizer's original shot.
In December, the U.S. health regulator had authorized Pfizer/BioNTech's updated shot as a third dose to those aged six months through four years, who have not completed their primary vaccination series or are yet to receive the third dose.
The health regulator's amended authorization is based on data from 60 children, from the expanded age group, who completed primary vaccination with three doses and received a booster shot of Pfizer/BioNTech, and showed an immune response to both the original SARS-CoV-2 virus strain and to Omicron BA.4/BA.5.
Shots for youngest children in the United States were only approved in June last year, making them the last group to become eligible for vaccination. Government data shows that only 2.7% children under the age of two and less than 5% of children aged two to four years who are eligible have completed their primary vaccination series as of Nov. 30, representing a slow uptake of the initial vaccine doses in young children.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.